Galderma Group AG

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
$22.9B
Website
http://www.galderma.com/

Restylane Perlane to Shape the Nasal Dorsum and/or Nasal Root

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2014-08-15
Last Posted Date
2022-08-26
Lead Sponsor
Galderma R&D
Target Recruit Count
132
Registration Number
NCT02216851

CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris

Phase 3
Completed
Conditions
Interventions
First Posted Date
2014-07-14
Last Posted Date
2019-11-14
Lead Sponsor
Galderma R&D
Target Recruit Count
453
Registration Number
NCT02189629
Locations
🇭🇺

Galderma Investigational Site, Szolnok, Hungary

🇨🇿

Galderma Investigational site, Praha 1, Czechia

Plaque Psoriasis Study in Pediatric Subjects

First Posted Date
2014-07-10
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
19
Registration Number
NCT02186665
Locations
🇧🇪

UCL Saint Luc, Brussel, Belgium

🇩🇪

University of Tübingen, Tubingen, Germany

🇺🇸

Dermatology and Laser Center of Charleston, Charleston, South Carolina, United States

and more 31 locations

A Post Market Evaluation After Treatment of Nasolabial Folds

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2014-07-02
Last Posted Date
2022-08-25
Lead Sponsor
Galderma R&D
Target Recruit Count
114
Registration Number
NCT02179736
Locations
🇨🇳

Plastic Surgery InstituteNo, No. 33 Badachu Road, Shijingshan District, Beijing, China

Dose-Escalation of Botulinum Toxin in Subjects With Osteoarthritis of the Knee

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-05-15
Last Posted Date
2022-08-25
Lead Sponsor
Galderma R&D
Target Recruit Count
22
Registration Number
NCT02139319

(Macrolane VR30) in Buttocks Reshaping and contouringCellulite (Macrolane VR30) in Buttocks Reshaping and Contouring

First Posted Date
2014-05-01
Last Posted Date
2022-08-26
Lead Sponsor
Galderma R&D
Target Recruit Count
20
Registration Number
NCT02127723
Locations
🇧🇷

Dr Hexsel, Porto Alegre, RS, Brazil

Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

Phase 4
Completed
Conditions
Interventions
First Posted Date
2014-04-29
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
54
Registration Number
NCT02125279
Locations
🇺🇸

Johnson Dermatology, Fort Smith, Arkansas, United States

🇺🇸

Advanced Skincare Surgery & Medcenter, Burbank, California, United States

🇺🇸

University of South Florida, Tampa, Florida, United States

and more 13 locations

A Safety and Efficacy Study of Different Injections Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar Lines

Phase 4
Completed
Conditions
Interventions
First Posted Date
2014-04-09
Last Posted Date
2022-08-25
Lead Sponsor
Galderma R&D
Target Recruit Count
62
Registration Number
NCT02108158
Locations
🇸🇪

Göteborgs Plastikkirurgiska Center, Gothenburg, Sweden

🇸🇪

Anna Neuromuskulär Konsult, Uppsala, Sweden

Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.

Phase 3
Completed
Conditions
Interventions
First Posted Date
2014-02-27
Last Posted Date
2017-03-28
Lead Sponsor
Galderma R&D
Target Recruit Count
417
Registration Number
NCT02073448
Locations
🇯🇵

Galderma investigational site, Saitama, Japan

Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.

Phase 2
Completed
Conditions
Interventions
First Posted Date
2014-02-27
Last Posted Date
2017-03-28
Lead Sponsor
Galderma R&D
Target Recruit Count
236
Registration Number
NCT02073461
Locations
🇯🇵

Galderma investigational site, Fukuoka, Japan

© Copyright 2024. All Rights Reserved by MedPath